Introduction
During hematopoiesis the development of hematopoietic progenitor cells is controlled by transcription factors that induce complex signaling cascades required both for limited growth and for terminal dierentiation. One of these factors is encoded by the c-myb protooncogene. A subset of c-myb sequences transduced by the oncogenic retroviruses AMV and E26 encoding p48 v-myb and p135 gag-myb-ets , respectively, interferes with signaling cascades of some hematopoietic cell types. AMV v-myb transforms myelomonocytic cells in vitro and causes leukemia in virus infected birds (for a review, see LuÈ scher and Eisenman, 1990; Graf, 1992; Introna et al., 1994; Lipsick, 1996) . Myb proteins are transcription factors that contain a N-terminal DNA binding domain, a central transactivation domain and a C-terminal negative regulatory domain which is largely deleted in v-Myb (Klempnauer et al., 1982; Klempnauer and Sippel, 1987; Weston and Bishop, 1989; Kalkbrenner et al., 1990) . Deletion of this negative regulatory domain appears to contribute to v-Myb oncogenic activation (Grasser et al., 1991) . AMV v-myb still contains the heptad leucine repeat that resembles leucine zipper structures of b-ZIP proteins (Hurst, 1995) and which is part of the negative regulatory domain of c-Myb. While a synthetic peptide comprising this region adopts ahelical structure in solution (Ebneth et al., 1994) , formal proof that such a structure does exist in vivo awaits further studies.
The potential function of this leucine zipper for both the c-Myb and v-Myb protein activity has recently been studied by analysing speci®c mutants. Mutation of the third and fourth leucine residues of the zipper (L3 and L4, respectively) to prolines or alanines, aecting either zipper secondary structure or hydrophobicity, enhanced the transcription activating function of murine c-Myb in transient transfection assays (Kanei-Ishii et al., 1992) . Moreover, a recombinant cmyb retrovirus carrying the proline mutations showed an increased transforming capacity in a colony formation assay with hematopoietic cells from murine fetal liver. These observations led to the conclusion that transactivation and transformation by c-Myb are negatively regulated by the leucine zipper motif (KaneiIshii et al., 1992; Foos et al., 1993) .
Moreover, in vitro binding studies demonstrated that a c-myb speci®c leucine zipper peptide associates with nuclear proteins from HeLa cells and murine hematopoietic cells (Kanei-Ishii et al., 1992; Favier and Gonda, 1994) . The leucine zipper motif has also been implicated in homodimerization of the c-Myb protein (Nomura et al., 1993) . Such homodimers failed, however, to bind to DNA in vitro. Furthermore, homodimerization of c-Myb via the putative leucine zipper was postulated to negatively autoregulate c-Myb activity in transient transfection assays with reporter gene constructs containing a Myb Recognition Element (MRE; Nomura et al., 1993) . Interestingly, in other studies Myb proteins were proposed to transactivate the hsp70 promoter (which does not contain an MRE) through amino acid residues contained in the leucine zipper domain (Foos et al., 1993; Kanei-Ishii et al., 1994) .
All these observations led to the conclusion that the leucine heptad repeat in c-Myb is involved in regulating normal development of hematopoietic cells presumably through interaction with speci®c cellular proteins (Favier and Gonda, 1994; Gonda et al., 1996) . In v-Myb the leucine repeat together with other Cterminal sequences were found to be required for oncogenic activity in vitro (Ibanez and Lipsick, 1988 ).
More recent work demonstrated that the FAETL region, which is a part of the leucine repeat, is essential for both transcriptional activation and in vitro transformation by v-Myb (Fu and Lipsick, 1996) . However, the integrity of the v-Myb leucine zipper motif was apparently not important for myelomonocytic cell transformation in vitro (Fu and Lipsick, 1996) .
We have recently generated and analysed, using in vitro and in vivo assays, a number of C-terminal AMV v-myb mutants (MD and MD, unpublished) . A series of these mutants transformed myeloid cells in tissue culture but failed to induce leukemia in vivo. Here we present the analysis of one of these mutants, vMyb L3,4A , where the leucines Leu 325 and Leu 332 contained in the heptad leucine repeat of v-Myb were replaced by alanines. The study points to a pivotal role of the leucine repeat for v-myb induced leukemogenesis in vivo. We also provide ®rst evidence that the v-Myb leucine repeat region binds cellular protein factors that might be involved in conferring v-Myb speci®c activities. , Figure  1 ). The v-myb L3,4A gene was introduced into the pneoAMV retroviral vector (Lipsick et al., 1986) replacing wild type v-myb speci®c sequences to generate pneoAMV L3,4A . Virus stocks of mutant vector and wild type control were obtained by calcium phosphate transfection of pneoAMV L3,4A and pneoAMV DNA, respectively, (together with MAV-1 helper virus DNA; Pecenka et al., 1988) into QT6 ®broblasts, and neo-resistant virus producing cells were selected in the presence of G418. Virus titers of tissue culture supernatants of neo-selected cells were determined by measuring the number of G418-resistant colonies after infection of QT6 cells with serial dilution of viral stocks.
Results

Leu
To analyse the leukemogenic potential of v-myb
, newborn Brown Leghorn chicks were inoculated intravenously with pneoAMV L3,4A virus samples bearing the same titer as wild type pneoAMV virus (10 4 G418-resistant units/ml). Table 1 shows that the L3,4A mutation results in a complete loss of leukemogenic potential of the v-myb oncogene. While 14 out of 15 chicks inoculated with wild type v-myb virus developed monoblastic leukemia within 2 to 3 weeks and died approximately 4 weeks later, none of the mutant virusinjected animals generated the disease even after 3 months. However, for some of the pneoAMV L3,4A infected animals we observed a transient`preleukemic' phase 30 days after infection which was characterized by an infrequent appearance of immature cells in the peripheral blood (data not shown). Yet, in all cases normal blood counts were restored within several days.
The L3,4A leucine zipper mutations do not aect v-Myb DNA binding and transactivation Previous studies established that transformation by vmyb requires the ability to bind to DNA and to activate transcription (Lipsick, 1996 , and references therein). To determine whether and if so which of these activities might be aected by the leucine zipper mutations in v-Myb L3,4A and thus might account for its loss of leukemogenic activity, DNA binding and transient cotransfection assays were performed. pneoAMV L3,4A vector DNA or pneoAMV control DNA were introduced into chicken embryo fibro- Figure 2b and data not shown). Finally, in CAT assays both mutant and wild type v-Myb eectively activated expression of a reporter gene containing the cognate 3xMRE binding site ( Figure 2c ). As expected no transactivation was seen for reporter gene constructs with a mutant MRE or for those lacking the recognition element. Thus, our data demonstrate that neither DNA binding nor transactivation eciency of v-Myb were impaired by the L3,4A mutations introduced. Moreover, in transfection assays the v-Myb L3,4A mutant behaved very similarly to an analogous c-Myb L3,4P mutant described by Nomura et al. (1993) in that it was a more potent transactivator than wild type v-Myb at high eector plasmid concentrations (2 mg; Figure 3c Figure 3b ). Expression of v-Myb was as high as that measured in the established AMV vmyb transformed cell line BM2.
Morphologically, both v-myb L3,4A and wild type vmyb transformed cells resembled monoblasts as revealed by cytochemical staining (Figure 3c ). To further support this contention, cells were analysed at day 20 for expression of myelomonocytic cell-speci®c cell surface markers by¯ow cytometry using a panel of monoclonal antibodies (Table 2 ). Both v-myb L3,4A mutant and wild type v-myb cells expressed high levels of surface antigens detected by MC51-2, MC47-83, MC22-3, and 5M19 monoclonal antibodies. Expression of a macrophage speci®c antigen detected by the K1 monoclonal antibody was much lower but again the same for both L3,4A and wild type v-myb cells, indicating that v-myb L3,4A cells had not further advanced in dierentiation (at least as measured by expression of K1 antigen). Additionally, cells expressed moderate levels of MHC class II and of the cell adhesion molecule BEN/DM-GRASP, and high levels of b 1 -integrin. Furthermore, such cells did not express the cell adhesion molecule HEM-CAM while BM2 cells did (data not shown).
The transforming potential of v-myb L3,4A was also evaluated in colony assays. 24 h after infection cells were seeded in semisolid methocel medium. At day 10 colony size and number of colonies observed for both L3,4A mutant and wild type v-myb were the same cells was consistently found and highly reproducible in several independent bone marrow infections and colony assays.
Finally, virus stocks produced by the in vitro transformed v-myb L3,4A monoblasts (10 5 G418-resistant units/ml) were tested for their potential to induce leukemia in newborn Brown Leghorn chicks (two groups of 15 birds) and 12 day old Brown Leghorn embryos (two groups of 8 embryos). It was found that wild type v-myb virus was highly leukemogenic with almost 100% penetrance while none of the L3,4A mutant v-myb virus infected animals developed leukemia. This ®nding is in line with the results presented above ( Table 1 ) and reemphasises that vmyb L3,4A is nonleukemogenic in vivo. The eect of relCM and cMGF on v-myb L3,4A cell growth was also evaluated in 3 H-thymidine incorporation assays. Growth of v-myb L3,4A cells was more sensitive to reduced serum concentration than that of wild type v-myb cells or of the v-myb transformed BM2 cell line (Figure 5b ). However, optimal concentrations of relCM or cMGF eectively enhanced 3 H-thymidine incorporation of v-myb L3,4A cells to levels which were similar to those observed for wild type v-myb cells. Thus, growth of v-myb L3,4A cells depends critically upon the presence of exogenous growth factors. Additionally, in these experiments vmyb L3,4A cells required higher cMGF concentrations than wild type v-myb cells (7.5 ng/ml versus 1 ng/ml, Figure 5c ) to achieve the same growth response. cells; relCM, however, contained substantial growth promoting activity to rescue this de®ciency. Thus, all these experiments point to the hypothesis that relCM contains factors other than cMGF that are important for ecient growth of v-myb transformed cells in culture (see also BM2 cells in Figure 5b ).
Loss of growth potential of v-myb L3,4A cells at 428C
There is ample evidence that leucine zipper structures provide interfaces for protein ± protein interactions. Additionally, binding of host cell proteins to a homologous region in c-Myb was demonstrated previously (Favier and Gonda, 1994; Gonda et al., 1996) . Therefore we reasoned that substitution of Leu 325 and Leu 332 in the v-Myb L3,4A protein by alanine residues might, while preserving the overall structure of the leucine zipper domain, weaken its interaction with a putative binding protein which is required for full transforming activity of v-Myb (see also Discussion). Additionally, this interaction might be further compromised or even lost at elevated temperatures and thus substantially aect growth of v-Myb L3,4A cells. To test this hypothesis v-myb L3,4A cells (day 25 of culture) were seeded at 378C and 428C and cumulative cell numbers were determined. Cells transformed by wild type v-myb served as an experimental control. As expected from the experiments described above, at 378C v-myb L3,4A cells grew less eciently than wild type cells was severely compromised and there was no overall increase in cell numbers irrespective of the presence or absence of cMGF (Figure 6a ). No such eect of temperature was seen for wild type v-myb cells which at 428C showed optimal growth rates. Cessation of v-myb L3,4A cell growth was due to an increased rate of cell death which was somewhat reduced in the presence of cMGF; a few dierentiated cells were also observed (Figure 6b and data not shown). In conclusion, temperature shift to 428C abolishes the growth promoting activity of the L3,4A mutant v-myb which might very well explain its loss of leukemogenic potential since 428C represents the body temperature of the chicken. Figure 7 shows that wild type v-Myb eectively binds to two nuclear proteins of 26 kD and 28 kD molecular weight (in the following referred to as p26 and p28); no speci®c binding to proteins in the cytoplasmic fraction was observed (not shown). Most importantly, the v-Myb L3,4A protein exhibited 2 ± 3 times reduced in vitro binding anity when compared to wild type v-Myb as determined by PhosphorImager quanti®cation. Additionally, the binding anity for the leucine zipper deletion mutant DLZ was 15 to 20 times lower. Deletion of other protein domains residing N-terminal to the leucine zipper left vmyb binding to p26 and p28 unaected (data not shown).
To extend these studies co-immunoprecipitation experiments were performed. Figure 7c shows that p26 and p28 are eectively co-immunoprecipitated with v-Myb from nuclear extracts of v-myb transformed cells using an anti-myb speci®c antibody. A virtually identical result was obtained with CEF transiently transfected with a v-myb expression vector and not with empty vector control (data not shown). Additional bands corresponding to other protein factors were also observed (Figure 7c ) which might, however, be due to unspeci®c binding. Furthermore, it is not clear at present whether p26 and p28 represent two distinct or two related proteins, or two modi®ed forms ; DLZ, v-Myb deletion mutant not containing the leucine zipper domain as in (a). (c) p26 and p28 proteins were co-immunoprecipitated from nuclear extracts of wild type v-myb transformed cells using a v-Myb speci®c polyclonal antibody (anti-myb). Preimmune serum was used as control (control). Nuclear extract prior to immunoprecipitation (input). Samples were separated by SDS ± PAGE and proteins detected with in vitro synthesized 35 S-methionine labelled v-Myb protein by Far Western as in (a) V-Myb leucine zipper in myeloid leukemia P Bartu Êne Ïk et al of one protein product. These questions can be answered once the respective cDNA have been molecular cloned. Thus, we provide initial evidence that v-Myb speci®cally interacts with two cellular proteins present in nuclei of v-Myb transformed cells, p26 and p28, via the leucine zipper domain. This interaction is compromised in v-Myb L3,4A and almost lost in the mutant v-Myb not containing the leucine zipper region.
Discussion
The goal of the present study was to examine a potential contribution of the heptad leucine repeat domain of v-Myb for its activity as an oncoprotein using in vivo and in vitro assays. Here we demonstrate that speci®c mutations that change Leu 325 and Leu 332 of the heptad repeat to alanine residues completely abolish the leukemogenic potential of v-Myb in virus infected animals. Thus, in addition to DNA binding and transactivation domains, the v-Myb leucine heptad repeat region is indispensable for v-myb oncogene activity in vivo.
V-myb L3,4A transformed monoblasts could, however, be generated in vitro by retroviral infection of chicken bone marrow cells with the very same retroviral vector. Additionally, our in vitro studies provided ®rst clues as to the defect that might lead to the loss of leukemogenicity of v-myb L3,4A . It was found that at 378C v-myb L3,4A cells grew slower than wild type v-myb cells while some cell death also occured. Most importantly, at 428C v-myb L3,4A cells ceased proliferation and exhibited an even higher rate of cell death. Since 428C represents the physiological body temperature of avian species, the temperature-sensitive phenotype of v-myb L3,4A might well explain its loss of leukemogenic potential in virus infected animals. Although the underlying mechanism of the v-myb L3,4A phenotype remains elusive, several possibilities can be envisaged to explain our ®ndings. First, the mutations introduced might change the overall structure of the vmyb L3,4A protein which only marginally aects its transforming activity at 378C but renders it completely inactive at 428C. We consider this possibility rather unlikely since the leucine to alanine mutations introduced involve rather subtle changes in amino acid sequence and hydrophobicity, and by computer analysis were predicted not to aect the overall ahelical structure of this protein domain. Second, the heptad leucine repeat of v-Myb, and more speci®cally Leu 325 and Leu
332
, might serve as an interface for interaction with another protein factor which is essential for v-Myb oncoprotein activity. This interaction might be somewhat compromised at 378C and lost at 428C, impairing only marginally growth of v-myb L3,4A cells at 378C while the eect might be more pronounced at 428C. In this paper we provide initial evidence for such an hypothesis.
Several biochemical properties of the v-Myb L3,4A
protein were analysed. It was found that in vitro DNA binding and transactivation potential of vMyb L3,4A were not aected. The L3,4A mutation did, however, diminish the interaction of the v-Myb L3,4A protein with two host cell proteins, p26 and p28, in Far Western blotting experiments. A speci®c interaction of cellular proteins with the heptad leucine repeat was described before for the murine c-Myb protooncoprotein (Favier and Gonda, 1994; Gonda et al., 1996) . However, these c-Myb interacting proteins appear to be dierent from those described in this paper for v-Myb, at least as judged by protein size. This ®nding is surprising in light of the fact that the amino acid sequence of the c-Myb heptad repeat region is highly conserved in v-Myb. A possible explanation might be that the Gonda group used a dierent assay system for isolation of Myb interacting proteins and also a dierent cell line as a source for cellular factors. The p26 and p28 proteins described in this paper are also dierent from c-Myb and v-Myb, indicating that homodimer or heterodimer formation does not occur, at least under the experimental conditions used. Additionally, the interaction of the co-activator protein CBP with Myb proteins (Dai et al., 1996; Oelgeschlager et al., 1996) involves a protein domain in Myb which is dierent from that of the heptad repeat region (Wolfes, H, personal communication). Finally, we suggest that other parts of the v-Myb protein (residing outside of the leucine zipper) might also contribute to binding of p26 and p28, since deletion of the leucine zipper region did not entirely abolish this interaction.
One of the most interesting aspects of the v-myb
phenotype among the various properties of v-myb L3,4A cells analysed are the altered growth properties. Outgrowth of v-myb L3,4A transformed cells occurred at about the same time as for wild type v-myb cells, both in mass culture and colony assays. Additionally, vmyb L3,4A was as eective as wild type v-myb in blocking myeloid cell dierentiation at the monoblast stage. Mutant L3,4A v-myb transformed cells were, however, compromised in proliferation and showed reduced growth rates in both mass culture and colony assays. Furthermore, in colony assays v-myb L3,4A cells stopped proliferating after about 14 cell divisions, while in mass cultures massive cell death occurred at that stage followed by clonal selection and further growth. Interestingly, following addition of growth factors (e.g. rel cell-conditioned medium, relCM or cMGF) v-myb L3,4A cells grew as eciently as wild type v-myb cells (without the factor) both in mass culture and colony assays. This ®nding suggests that the defect in the proliferative potential and the increased factor dependence is an inherent property of the v-Myb L3,4A protein that can be rescued by addition of cMGF or factors contained in rel cell-conditioned medium. Thus, our results implicate the leucine heptad repeat of v-myb in conferring growth factor independence in v-myb monoblasts e.g. by activating speci®c target genes which encode growth factor activities that support sustained growth of v-myb cells in an autocrine fashion. Alternatively, the v-Myb leucine zipper domain might be required for the activation of genes involved in intracellular signalling that render v-myb transformed cells independent of external growth promoting stimuli. Such ideas would be in line with the fact that myeloblasts transformed by E26 v-myb-ets (which due to the myb-ets fusion has deleted the leucine heptad repeat region) are also dependent on exogenous factors for ecient growth in vitro. However, while our data demonstrate the importance of the v-myb leucine zipper region for leukemogenicity in vivo and factor-independent growth in vitro, analogous mutations in c-myb apparently have opposing eects (Kanei-Ishii et al., 1992; Gonda et al., 1996) for reasons that are presently unknown.
Expression of cMGF was shown to be dependent on NF-M (C/EBPb) and tyrosine kinase activated AP-1 (Sterneck et al., 1992b) , although several potential Myb binding sites also occur in the cMGF promoter (Sterneck et al., 1992a) . Thus cMGF might be one of the genes that is activated by v-Myb proteins. However when v-myb L3,4A cells were incubated at 428C, no cell proliferation occurred irrespective of the presence or absence of cMGF. Furthermore, so far no cMGF speci®c transcripts were detected in both v-myb L3,4A and wild type v-myb transformed cells indicating that growth factors other than cMGF are involved (N Koritschoner and PB, unpublished). Activation of such genes might require the interaction of v-Myb L3,4A with a putative protein factor which, however, in v-Myb L3,4A is severely compromised or lost at elevated temperatures due to the L3,4A mutations (see above). Alternatively, AMV v-myb might, similarly to E26 v-myb-ets (Frampton et al., 1996) activate expression of the anti-apoptotic bcl-2 gene, and this activation might be compromised in v-Myb L3,4A cells leading to the observed phenotype. However, while AMV v-myb transformed monoblasts isolated from virus infected leukemic animals express bcl-2 mRNA, no bcl-2-speci®c transcripts were detected in the v-myb L3,4A and wild type v-myb monoblasts described here (P Pajer and MD, unpublished observation). Whether other members of the bcl-2 family with anti-apoptotic activity are expressed in these cells still remains to be investigated.
Our results are in apparent con¯ict with a similar study performed by Fu and Lipsick (1996) who de®ned a 10 amino acid region of v-myb (the`FAETL' motif) whose integrity is indispensable for v-myb speci®c in vitro transformation of hematopoietic cells from 12 to 13 day chicken embryonic yolk sac. Interestingly, the FAETL motif partially overlaps with the leucine zipper structure. However, in the report of Fu and Lipsick (1996) mutations within the leucine zipper domain were found not to be deleterious to myelomonocytic cell transformation in culture. We provide the following explanations to relate those results with our ®ndings reported here. First, Fu and Lipsick assayed the transforming capacity of various mutant v-Myb proteins at 378C and also used embryonic yolk sac cells rather than bone marrow. Under these conditions related, although not completely identical, mutations generated by Fu and Lipsick within the leucine zipper domain exhibit similar properties to the v-myb L3,4A mutant as described in this paper, like e.g. colony size in colony assays and dependence on exogenous growth factors. Second, in our study oncogenic activity of v-myb proteins was assayed in vitro at elevated temperatures (428C) and, additionally, in virus infected animals which provided more physiological conditions. Given the temperature-sensitive phenotype of the vmyb L3,4A mutant, we would predict that some of the heptad repeat mutants of Fu and Lipsick, when assayed at elevated temperature or in vivo, might also be inactive for transformation. Finally, a precise delineation of the amino acid residues required within the leucine zipper and FAETL domain of v-Myb for vmyb speci®c transformation awaits the identi®cation of the protein factors that bind to this region. Our ®nding that implicate the v-Myb leucine zipper in interaction with two cellular proteins, p26 and p28, is a ®rst step in that direction.
Our data clearly reveal that transformation experiments in tissue culture can provide only partial information about the leukemic potential of the vmyb oncogene. In vivo control mechanisms do exist that eciently suppress proliferation of transformed cells which otherwise would extensively grow in vitro. Our data suggest that the leucine zipper motif of wild type v-Myb but not its L3,4A mutant carries the function(s) which enable transformed monoblasts to escape such control mechanisms. Such function(s) are e.g. extended survival rates, higher proliferation capacity and growth factor independence which all might have a common origin provided by sustained activation of components of the cell cycle machinery. Finally, the loss of leukemic cell transformation in vmyb L3,4A is not exceptional. We have generated several other v-myb mutants that block myeloid cell differentiation, induce proliferation and extend the life span of transformed myeloid cells in vitro similarly to wild type v-myb, yet these mutants do not induce leukemia in virus infected chicks (MD and MD unpublished) . Thus, there are clearly some functions of v-myb that are dispensable for growth of transformed cells in tissue culture but that are absolutely required for leukemia formation in vivo.
Materials and methods
Plasmid constructs
Retroviral vectors: pneoAMV vector containing the AMV v-myb gene (Lipsick et al., 1986) was used for transient transfections in chicken embryo ®broblasts (CEF) and for generating pneoAMV virus stocks in QT6 cells (see below). To generate the v-myb L3,4A mutant gene, a v-myb-speci®c SalI-XbaI fragment was subcloned into pBluescript vector and mutagenized by PCR using appropriately designed primers. The Leu 325 codon CTC was mutated into GCA to generate Ala 325 and a unique NsiI site at this position; similarly the Leu 332 CTC codon was changed to GCC encoding Ala 332 . The integrity of the mutant sequences was con®rmed by DNA sequencing. The mutant fragment was then inserted into pneoAMV vector to generate pneoAMV L3,4A . Reporter constructs: Synthetic oligonucleotides containing wild type and mutant mim-1A Myb Recognition Elements (MRE; Ness et al., 1989; Chen and Lipsick, 1993) were synthesized, oligomerized and their head-to-tail trimers (3xMRE and 3xMREm, respectively) were inserted into pCAT-b-TATA reporter plasmid. pCAT-b-TATA (kind gift of JD Engel) is a derivative of pcAT-Basic (Promega, MA) containing the rabbit b-globin TATA element. pRSV-bGal plasmid DNA (Edlund et al., 1985) was used as internal control to normalize for transfection eciency.
Templates for in vitro transcription/translation were prepared by inserting the EcoRI-XbaI fragments of AMV v-myb into pGEM-4Z vector (Promega, MA), thereby generating pEX-myb. pEX-myb-L3,4A and pEX-myb-DLZ plasmids are derivates of pEX-myb containing the L3,4A mutation (see above) and an in frame deletion of a NsiI-BalI fragment encompassing 325 ± 362 codons of the leucine zipper domain, respectively. The ATG triplet that encodes Met 124 in full length v-myb and is located 10 nucleotides downstream of the EcoRI site serves as initiation codon for protein biosynthesis in the in vitro transcription/translation reaction (see below).
Cell culture
CEF, QT6 cells and v-myb transformed monoblasts were grown in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 8% fetal calf serum (FCS, Sebak, Switzerland) and 2% chicken serum (Sigma), 20 mM HEPES pH 7.3 and 100 units/ml Penicillin/Streptomycin (Gibco-BRL) referred to as standard growth medium.
Virus stocks were obtained by calcium phosphate transfection of 10 mg pneoAMV vector DNA (together with 1 mg MAV-1 helper virus DNA, pATMAV-1; Pecenka et al., 1988) into QT6 ®broblasts and neo-resistant virus producing cells were selected in the presence of G418 (600 mg/ml; Gibco-BRL). Cells were trypsinized and used in further experiments. Virus titers of tissue culture supernatants of neo-selected QT6 cells and transformed monoblasts (see below) were determined by measuring the number of G418-resistant QT6 ®broblast colonies after infection of QT6 cells with serial dilution of viral stocks.
To generate v-myb transformed monoblast, 10 6 virusproducing pneoAMV and pneoAMV L3,4A QT6 cells were treated with mitomycin C (1 h, 5 mg/ml; Sigma) and used for cocultivation with 20610 6 bone marrow cells prepared from a 5 day old chick. After 2 days nonadherent cells were recovered and cultured in standard growth medium at a density 3610 6 cells/ml. An outgrowth of v-myb transformed monoblasts was routinely observed at day 7 and cells were grown at 2610 6 cells/ml. Cell number and size were determined in regular time intervals using the multichannel cell counter and analyser system CASY-1 (SchaÈ rfe System, Reutlingen, Germany). For analysis of cell morphology cells were cytocentrifuged onto glass slides (700 r.p.m., 7 min, Cytospin 2, Shandon Inc, Pittsburgh, USA), ®xed in methanol and stained with DiQuick (Baxter, Switzerland). Cell preparations were rinsed with water and mounted with Entellan (Merck). Photographs were taken with Axiophot II microscope (Zeiss) and Kontron ProgRes 3012 CCD camera (Kontron, Munich, Germany) and processed using Adobe Photoshop software.
Colony formation and cell proliferation assays
Two days after in vitro infection 5610 5 non adherent bone marrow cells were seeded in semisolid Methocel medium containing DMEM, 0.8% Methyl cellulose, 8% FCS and 2% chicken serum, 20 mM HEPES pH 7.3 and 100 units/ml Penicillin/Streptomycin. Methocel medium was supplemented with 10 ng/ml of recombinant His-cMGF (see below) or 5% rel cell-conditioned medium (relCM) prepared from supernatants of c-rel expressing CEF (Beug et al., 1995) .
Cell proliferation was measured as rate of DNA synthesis by 3 H-thymidine incorporation as described (Leutz et al., 1984) . Brie¯y, cells (4610 4 cells/100 ml) were incubated in assay medium (DMEM supplemented with 2% FCS, 0.2% chicken serum, 20 mM HEPES pH 7.3, 100 U/ml Penicillin/ Streptomycin) with 0.8 mCi H-thymidine (speci®c activity 29 Ci/mmol; Amersham, UK) for 2 h at 378C, harvested onto ®lter plates and subjected to scintillation counting. Average values from triplicate samples were determined.
Leukemogenesis assay
Brown Leghorn C/E gs 7 chicken from leukosis free¯ocks (Hlozanek and Sovova, 1968) were infected with virus by injecting 0.5 ml of virus containing tissue culture supernatants (10 4 to 10 5 G418-resistant units/ml) into vena saphena. Virus titers refer to the number of G418-resistant foci obtained after infection of CEF or QT6 cells and G418 selection. Animals were inspected for leukemia formation by analysing peripheral blood smears and microhematocrites in regular time intervals.
Cotransfection transactivation assay CEF (6610 5 cells) were seeded onto a 60 mm Petri dish and incubated in standard growth medium. The following day cells were transfected with 5 mg of DNA (2 mg of pneoAMV expression vector plus 1 mg of pCAT-b-TATAbased reporter vector, 0.5 mg of pRSV-bGal, and 1.5 mg of pBluescript carrier DNA) using calcium phosphate transfection (Chen and Okayama, 1987) , 16 h post transfection, cells were rinsed and fed with fresh standard growth medium. At day 2 after transfection cells were harvested and cell extracts were prepared for EMSA and CAT ELISA assays. Cells transfected without pneoAMV expression vector were used as control. Aliquots of cell extracts (normalized for protein content) were analysed for v-myb expression by Western blotting and for v-Myb speci®c DNA binding activity in EMSA (see below). CAT activity was determined by ELISA assay (Boehringer Mannheim) and plotted as fold activation of control (no expression vector transfected).
Flow cytometry
Surface antigen expression of v-myb monoblasts was analysed by¯ow cytometry. Therefore 10 6 cells were recovered, washed in PBS containing 1% bovine serum albumin (BSA, Fraction V, Sigma) and reacted with speci®c monoclonal antibodies (1 h), followed by reaction with FITC-conjugated anti-mouse IgG (Fc speci®c; 45 min; Sigma). The following antibodies were used: MC51-2, MC47-83, MC22-3 (Kornfeld et al., 1983) ; 5M19 (Olson and Ewert, 1994); K1 (Kaspers et al., 1993) ; monoclonal antibodies speci®c to MHC class II b-chain (clone 2G11; Kaufman et al., 1990 ; BEN/DM-GRASP (Corbel et al., 1992) ; HEM-CAM (Vainio et al., 1996) and b1-integrin (Sigma). Cells were washed twice and resuspended in PBS containing 1% BSA and propidium iodide (2 mg/ml; Sigma). For¯ow cytometric analysis a FACScan device with Cell Quest Software (Calibur, Becton Dickinson) were used.
Expression and puri®cation of recombinant his-tagged chicken myelomonocytic growth factor (His-cMGF) PCR primers 5'-CGGGATCCGCTCCGCTGGCCGAG-CT-3' and 5'-CGGGATCCTCTAGAGGCGGGCGAG-GTGC-3', MGF-1 and MGF-2, respectively, were synthesized and used for PCR ampli®cation of the cMGF cDNA (Leutz et al., 1989 ) not containing the signal peptide sequences (20 cycles, 10 pmoles of primer, 10 ng of linearized template and 2.5 U of Taq DNA polymerase; Boehringer Mannheim). The 550 bp PCR product was digested with BamHI restriction endonuclease, isolated by gel electrophoresis and ligated into the prokaryotic expression vector pETH2a (a kind gift of M Busslinger, IMP, Vienna, Austria). This generated the expression plasmid pHis-cMGF which was used for transformation of T7 polymerase expressing BL21(DE3) cells. Induction of 21 kD His-cMGF protein synthesis by IPTG and purification of recombinant protein on a Ni 2+ -NTA agarose column was done according to the manufacturer's procedure (Qiagen, Germany) with some modi®cations as published before (Bartunek et al., 1996) .
Western blot analysis
Protein lysates were separated on a 10% SDS ± PAGE gel and blotted onto nitrocellulose membranes (Schleicher and Schuell, BA85). After blocking membranes overnight in TBS (25 mM Tris-HCl pH 7.4, 137 mM NaCl, 5 mM KCl,
